Product Launch Tracker: HCPs celebrated the FDA’s approval of FluMist

18.10.2024 | Tracker

Product Launch Tracker: HCPs celebrated the FDA’s approval of FluMist

During September 2024, CREATION.co tracked the global conversations of 1,708 healthcare professionals (HCPs) who posted 2,704 times about the launches and approvals of new products.

HCP mentions of product launches on X in September 2024

On 20 September, the FDA approved AstraZeneca’s FluMist Nasal Spray for at-home administration. 88 HCPs reacted to the news by sharing about the approval. Since the vaccine does not need to be administered by a healthcare professional, 48 HCPs celebrated this highlighting its ease and convenience alongside noting that the nasal spray is also accessible for ‘needle-shy people.’

Approval of Osimertinib

On 25 September, the FDA expanded the approval of Osimertinib following the results of the LAURA trial. 60 HCPs shared 70 times about the approval on X. Medical Oncologist, Antonio Calles, highlighted its ‘massive benefit’ for patients with locally advanced stage III EGFR+ non-small cell lung cancer.

Excitement for the approval of Cobenfy

On 27 September, the FDA approved Bristol Myers Squibb’s, first-in-class treatment of schizophrenia, Cobenfy. 68 HCPs posted about the approval of Cobenfy in 72 posts. Psychiatrist, Prakash Masand, expressed his excitement towards the approval and stated that it is ‘a truly innovative mechanism of action.

The three most shared stories from HCPs discussing product launches in September were:

  1. An FDA Breakthrough Device Designation for Neuralink’s Blindsight device – 41 posts.
  2. An FDA press release announcing the approval of FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration – 37 posts.
  3. An FDA press release announcing the approval of pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma (MPM) – 37 posts.

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • CREATION Pinpoint® listened to the discussions amongst online HCPs of pharmaceutical product launches and drug approvals between 1 September and 30 September 2024.  
  • The data included mentions of drug approvals by the FDA, EMA, MHRA, NICE, and CHMP, as well as HCPs’ use of the phrase ‘drug approval’ in their posts.
  • Between 1 and 30 September 2024, 1,708 online HCPs worldwide made 2,704 references to new pharmaceutical product launches and drug approvals. 

 

Share this article

Meet the Author

Jessica Fernandes

After attaining a 1st class degree in Theology from Durham University, Jessica returned to Kent to join the graduate programme here at CREATION.co. She uses her research and analytical skills to inform health strategy and serve clients.

Outside of work, Jessica loves to travel and visit historical landmarks. She also enjoys mini-golf and going out for brunch with friends and family.

Suggested next


01.10.2020 | Article

HCPs commend Pharma and seek to reassure the public over vaccine safety concerns

Discover what healthcare professionals (HCPs) think about COVID-19 vaccines

By Laura McIntyre

HCP attitudes & behaviors relative to Meningitis B vaccines are correlated to evidence-based guidelines

18.10.2018 | Article

HCP attitudes & behaviors relative to Meningitis B vaccines are correlated to evidence-based guidelines

HCP attitudes & behaviors relative to Meningitis B vaccines are correlated to evidence-based

By Greg Matthews

View all articles >